Together, We Can
Each year the Washington Cancer Institute at MedStar Washington Hospital Center diagnoses >2,000 people with new cancers. Approximately 15% of all patients enroll in a clinical trial. In addition, 56% of all enrollments are in minority populations, and this number makes the Washington Cancer Institute a national leader in minority cancer care. Approximately 18% of our African-American/Black women with breast cancer are enrolled on clinical trials, compared with only 1% nationally. Here are some things that funding is currently supporting:
Dr. Ami Chitalia initiated a study with the cardio-oncology team at MedStar Washington Hospital Center to assess breast cancer survivors’ risk of cardiovascular disease in the years following treatment.
In 2020 Dr. Asma Dilawari completed enrollment of a collaborative pilot with Paxman Scalp Cooling Company that offered an FDA-approved supportive treatment to prevent hair loss in black women receiving chemotherapy for breast cancer. The treatment was offered free of cost, it normally carries a possible cost to patients of $2000.00 and is not covered by most insurances. Initial results of this study indicated that the treatment does not work in the same way for black hair types. Because of these findings, Paxman has taken measures to try to improve their caps and delivery.
Dr. Shenoy from the Washington Cancer Institute along with collaborators at the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), are conducting a study in cancer patients with early-stage cancers aimed to predict long term adverse outcomes to cancer treatments. By 2025 it is predicted that there will be >20 million cancer survivors in the US. How to monitor cancer survivors for long-term problems related to their cancer therapy provided to cure their cancer is unknown. Data from this project can inform future studies looking to prevent future medical problems in cancer survivors and even determine if certain cancer patients should avoid certain treatments due to the risk of long-term disease.
MedStar Washington Hospital
The Washington Cancer Institute, a part of MedStar Washington Hospital Center, treats more cases of cancer than any other cancer institute in the region. As it is the largest outpatient cancer center in the District of Columbia, serving nearly 82,000 outpatient visits with about 3,000 new cases of cancer diagnosed annually. No matter what the barriers may be for a patient, Washington Cancer Institute treats each individual and their family with the highest quality, compassionate care.
MedStar Washington Hospital Center, Washington Cancer Institute is a regional leader and national model for patient-focused cancer diagnosis and treatment that provides the highest quality, and latest medical advances in cancer diagnosis and treatment. Washington Cancer Institute delivers comprehensive, interdisciplinary care including surgical, radiation and medical oncology services, patient/family support services, cancer screening, education, and clinical trials.
* MedStar Washington Hospital Center is a registered 501(c)3 organization. Tax identification number: 52-1272129. All eligible contributions are tax-deductible to the extent of the law. All gifts are non-refundable.
Here are a few ways your fundraising efforts support patients, doctors, and researchers:
- Expert Physicians – The Institute physicians are national experts in cancer screening, diagnosis, and treatment.
- Customized Support Services – Cancer is life-changing. The Institute’s goal is to provide compassionate and professional care to each patient, promote the healing process, and support patients every step of the way.
- Clinical Trials – The Institute provides patients access to many clinical trials, which offer new treatments for cancer.
- A Healing Environment – The Institute is a national model and regional leader of patient-centered cancer diagnosis and treatment.
- Technology – The Institute is one of the nation’s most technologically advanced cancer centers and is a national model and regional leader of cancer treatment.